Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease
← catalyst calendarNCT06851806 · readout in 192 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Prevention
Enrollment
138estimated
Sites
6
Country
India
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-10 | actual | When the study began enrolling |
| Primary completion | 2027-02-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Respiratory Syncytial Virus (RSV)
Intervention
- Drug: Palivizumab 15 mg/kg
Primary outcome
what the primary-completion date above is the date OFTo assess the safety of palivizumab prophylaxis when administered to preterm infants (≤ 35 wGA), children with BPD (< 24 months) and/or children with haemodynamically significant CHD (< 24 months).
measured screening to day 151
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed